Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction
- PMID: 23076661
- DOI: 10.1007/s11096-012-9717-0
Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction
Abstract
Case description: A 75-year-old man developed rhabdomyolysis and acute renal failure during atorvastatin therapy. All medications were discontinued and the patient was treated with intermittent hemodialysis throughout the course of hospitalization. After four weeks, patient's kidney function tests and serum myoglobin levels decreased to normal values and muscle weakness gradually disappeared. Genotyping results showed that the patient had a single-nucleotide polymorphism within genes encoding the organic anion-transporting polypeptide 1B1 and ATP binding cassette sub-family B member 1, which predisposed him for statin-induced myopathy. He was also a poor metabolizer of cytochrome P450 2C19. Concomitant therapy with pantoprazole could have resulted in the inhibition of cytochrome P450 3A4-mediated metabolism of atorvastatin and contributed to the development of rhabdomyolysis.
Conclusion: The case illustrates the clinical relevance and relationship between pharmacogenetic and pharmacokinetic factors in the development of statin-induced myopathy.
Similar articles
-
[Genetic marker of statin-induced rhabdomyolysis].Yakugaku Zasshi. 2011 Feb;131(2):247-53. doi: 10.1248/yakushi.131.247. Yakugaku Zasshi. 2011. PMID: 21297370 Review. Japanese.
-
Statin-associated acute interstitial nephritis and rhabdomyolysis.Saudi J Kidney Dis Transpl. 2014 May;25(3):659-60. doi: 10.4103/1319-2442.132230. Saudi J Kidney Dis Transpl. 2014. PMID: 24821172 No abstract available.
-
Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.Am J Med. 2002 Apr 15;112(6):505. doi: 10.1016/s0002-9343(01)01135-4. Am J Med. 2002. PMID: 11959068 No abstract available.
-
Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.J Clin Pharmacol. 2011 May;51(5):784. doi: 10.1177/0091270010377504. Epub 2010 Jul 29. J Clin Pharmacol. 2011. PMID: 20671297 No abstract available.
-
HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview.Curr Drug Metab. 2021;22(5):328-341. doi: 10.2174/1389200222666210114122729. Curr Drug Metab. 2021. PMID: 33459228 Review.
Cited by
-
Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.Clin Pharmacokinet. 2018 Oct;57(10):1267-1293. doi: 10.1007/s40262-018-0650-9. Clin Pharmacokinet. 2018. PMID: 29667038
-
Optimising Seniors' Metabolism of Medications and Avoiding Adverse Drug Events Using Data on How Metabolism by Their P450 Enzymes Varies with Ancestry and Drug-Drug and Drug-Drug-Gene Interactions.J Pers Med. 2020 Aug 11;10(3):84. doi: 10.3390/jpm10030084. J Pers Med. 2020. PMID: 32796505 Free PMC article.
-
Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.Croat Med J. 2020 Apr 30;61(2):147-158. doi: 10.3325/cmj.2020.61.147. Croat Med J. 2020. PMID: 32378381 Free PMC article. Review.
-
Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?Hippokratia. 2015 Oct-Dec;19(4):332-7. Hippokratia. 2015. PMID: 27688698 Free PMC article.
-
Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database.Drug Saf. 2017 Oct;40(10):895-909. doi: 10.1007/s40264-017-0564-8. Drug Saf. 2017. PMID: 28681266
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical